Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Phapros TbkISX:PEHA +2.31%72 5-Year Yield-on-Cost % is 1.88 as of Aug. 08, 2026, which is 22% below its 10-year median of 2.41. GuruFocus rates ISX:PEHA with a GF Score™ of 72/100 and a GF Value™ of Rp382.43 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 513 Drug Manufacturers companies, PT Phapros Tbk ranks worse than 55.36% on this metric.
PT Phapros Tbk's yield on cost for the quarter that ended in Mar. 2026 was 1.88.
The historical rank and industry rank for PT Phapros Tbk's 5-Year Yield-on-Cost % or its related term are showing as below:
ISX:PEHA'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.84 Med: 2.41 Max: 14.8
Current: 1.88
During the past 13 years, PT Phapros Tbk's highest Yield on Cost was 14.80. The lowest was 0.84. And the median was 2.41.
ISX:PEHA's 5-Year Yield-on-Cost % is ranked worse than 55.36% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs ISX:PEHA: 1.88
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
PT Phapros Tbk 5-Year Yield-on-Cost % Related Terms
ISX:PEHA vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Phapros Tbk's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Phapros Tbk 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Phapros Tbk's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where PT Phapros Tbk's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of PT Phapros Tbk is calculated as
PT Phapros Tbk (ISX:PEHA) has a 5-Year Yield-on-Cost % of 1.88 as of Aug. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PT Phapros Tbk and its competitors. This is 22% below median its historical median of 2.41. Over the past decade, PT Phapros Tbk's 5-Year Yield-on-Cost % has ranged from 0.84 to 14.80. According to the industry distribution chart, PT Phapros Tbk ranks #284 out of 513 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is PT Phapros Tbk's 5-Year Yield-on-Cost % too high?
PT Phapros Tbk's current 5-Year Yield-on-Cost % of 1.88 is 22% below median its 10-year median of 2.41. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 14.80. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. PT Phapros Tbk's value of 1.88 is 17.9% below this industry median. Based on the distribution chart, PT Phapros Tbk ranks #284 out of 513 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PT Phapros Tbk has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Phapros Tbk's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Phapros Tbk ranks #284 out of 513 companies for 5-Year Yield-on-Cost %. This places PT Phapros Tbk in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. PT Phapros Tbk's value of 1.88 is 17.9% below this benchmark. Historically, PT Phapros Tbk's own 5-Year Yield-on-Cost % has ranged from 0.84 to 14.80 over the past decade. While the company's 10-year median is 2.41 vs. the industry median of 2.29, PT Phapros Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Phapros Tbk's current 5-Year Yield-on-Cost % of 1.88 is 17.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PT Phapros Tbk and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Phapros Tbk's current 5-Year Yield-on-Cost % is 1.88, which is 22% below median its own 10-year median of 2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Phapros Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Phapros Tbk (ISX:PEHA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp382.43, compared to a current price of Rp266.00 — trading 30.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.88, which is 22% below median its 10-year median of 2.41 and 17.9% below the Drug Manufacturers industry median of 2.29. PT Phapros Tbk's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For PT Phapros Tbk (ISX:PEHA), the current 5-Year Yield-on-Cost % is 1.88 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Phapros Tbk (ISX:PEHA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Phapros Tbk stock appears to be undervalued.
The current stock price of Rp266.00 is trading 30.4% below its estimated GF Value™ of Rp382.43.
GuruFocus considers PT Phapros Tbk to be Possible Value Trap.
Key valuation signals for ISX:PEHA:
5-Year Yield-on-Cost %: 1.88 (22% below median its 10-year median of 2.41)
GF Value™: Rp382.43 vs. price of Rp266.00 (30.4% below fair value)
Industry Position: 17.9% below the Drug Manufacturers median (#284 of 513)
No single metric tells the full story. See the ISX:PEHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Phapros Tbk is a pharmaceutical company in Indonesia. The company is engaged in the industrial/manufacturing sector by producing and/or trading medicines, health instruments, chemical goods, and other similar goods in import, export, and other kinds of industry. The company operates through Over Counter (OTC), Ethical, Generic Drugs Bearing (OGB), and Toll Manufacturing segments. It derives maximum revenue from OGB segment.
72GF Score
Get the complete analysis for ISX:PEHA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEHA has been successfully added to your 
